Health Condition 1: - Health Condition 2: N178- Other acute kidney failure
Conditions
Interventions
Intervention1: Atrasentan (Active): 0.75 mg per tablet, 1 tablet QD, Oral Route for 132 weeks
Control Intervention1: Placebo: Matching placebo film-coated round tablets, 1 tablet QD for 132 weeks
Sponsors
Chinook Therapeutics
IQVIA RDS India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Age and Sex Male and female subjects aged 18 and older at the time of signing the ICF prior to initiation of any study specific activities/procedures. Types of Subjects and Disease Characteristics Biopsy-proven IgAN that, in the opinion of the Investigator, is not due to secondary causes. Biopsy could have occurred at any point in time prior to study. A diagnostic report must be available for review by the Sponsor or designee. Receiving a maximally tolerated and optimized dose of a RAS inhibitor that has been stable for at least 12 weeks prior to screening. Investigator discretion should be used in determining maximally tolerated and optimized dose. Subjects who are intolerant to RAS inhibitors are eligible but will not exceed Approximately 5 percent of total population randomized. Total urine protein greater than or equal to 1g/day as measured via 24-hour urine collection at a central laboratory collected at Screening eGFR of at least 30 mL per min per 1.73 mL at screening based on the CKD EPI equation. Pregnancy and Contraception All fertile men and WOCBP must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of hormonal contraceptive agents must have been started at least 1 month prior to baseline. Informed Consent Willing and able to provide written informed consent and comply with all study visits and study procedures.
Exclusion criteria
Exclusion criteria: Subjects must meet NONE of the following exclusion criteria to be enrolled. Concurrent diagnosis of another cause of chronic kidney disease including diabetic kidney disease or another primary glomerulopathy. Clinical suspicion of rapidly progressive glomerulonephritis (RPGN) based on KDIGO guidelines or clinical suspicion of Henoch-Schonlein Purpura. Clinical diagnosis of nephrotic syndrome BNP value of more than 200 mg per mL at screening. Platelet count less than 80,000 per µL at screening. History of organ transplantation (subjects with history of corneal transplant are not excluded). Use of systemic immunosuppressant medications including including systemic corticosteroids (e.g., prednisone, prednisolone, etc.), mycophenolate, azathioprine, cyclosporine, tacrolimus, etc.; use of herbs such as Tripterygium Wilfordii Hook F, Caulis sinomenii and Sinomenium acutum; for more than 2 weeks in the past 3 months. Use of rituximab within the past 6 months. Confirmed blood pressure more than 150 mmHg systolic or more than 95 mmHg diastolic based on a mean of 3 measurements obtained at screening. Known history of heart failure or prior hospital admissions for conditions relating to fluid overload such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites. Known history of clinically significant liver disease or transaminase or bilirubin values more than twice the upper limit of normal. Subjects with treated hepatitis C can be considered for inclusion into the study upon consultation with the Sponsor’s Medical Monitor (or designee). Hemoglobin below 9 g per dL at screening or prior history of blood transfusion for anemia within 3 months of screening. History of malignancy unless cancer free for at least 5 years or nonmelanoma skin cancer not requiring ongoing treatment. A subject with curatively treated cervical carcinoma in situ is eligible for this study. Pregnancy, breast feeding, or intent to become pregnant during the study period and at least 1 month afterward for females. Intent to father a child or donate sperm during the study period and at least 1 month afterward for males. Have received any investigational agent or approved treatment for IgAN (other than a RAS inhibitor) including SGLT2 inhibitors within 1 month (or 5 half-lives of the agent, whichever is longer) prior to screening. If the investigational agent is a cytotoxic or immunosuppressive agent, then this washout period is 6 months. Concurrent clinically significant, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the Investigator or Sponsor’s Medical Monitor (or designee), might confound the results of the study or pose additional risk to the subject by their participation in the study. History of an alcohol or illicit drug-related disorder within the past 3 years.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effect of atrasentan versus placebo on change from baseline to Week 136 (4 weeks post cessation of randomized treatment) in estimated glomerular filtration rate (eGFR)Timepoint: Change from baseline to final study visit (Week 136) in eGFR, using the chronic kidney disease-epidemiology collaboration (CKD-EPI) creatinine equation.;To compare 2-year on-treatment rates of change in eGFR between atrasentan and placebo (eGFR slope Week 12 to Week 120 of randomized treatment)Timepoint: Rate of change in eGFR during 2 years on treatment as measured through a chronic slope calculated from values at Week 12 through to Week 120;3. To compare the total on-study rates of change in eGFR between atrasentan and placebo (eGFR slope from baseline to Week 136).Timepoint: Rate of change in eGFR during the study as measured through a total slope calculated from values at baseline to Week 136;Additional efficacy outcomesTimepoint: • Percent of subjects achieving proteinuria reduction to more than1 g per day at Week 24 and 40% decrease in UPCR from baseline. • Percent of subjects experiencing at least a 30% reduction in eGFR or reach end-stage kidney disease (ESKD) during the study. • Percent of subjects experiencing at least a 40% reduction in eGFR or reach ESKD during the study Safety. | — |
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of atrasentan versus placebo on proteinuria levels at Week 24Timepoint: The change in proteinuria (urine protein: creatinine ratio [UPCR] based on 24-hour urine collection) from baseline to Week 24 | — |
Countries
Argentina, Australia, Brazil, Canada, China, Colombia, Czech Republic, France, Germany, Hong Kong, India, Ireland, Italy, Japan, New Zealand, Poland, Portugal, Republic of Korea, Spain, Taiwan, United Kingdom, United States of America
Contacts
Public ContactShweta Pradhan
IQVIA RDS (India) Private Limited
Outcome results
None listed